Detail akcie Edwards Lifesci online

Business Summary: Edwards Lifesciences Corporation is a global structural heart innovation company. The Company is engaged in patient-focused medical innovations for structural heart disease and invests in research and development to transform care for those impacted by structural heart disease. Its products are categorized into groups, including Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart (Surgical). It develops transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. The Edwards SAPIEN family of valves includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra, and the Edwards SAPIEN 3 Ultra RESILIA systems, are catheter-based approaches for treating severe symptomatic aortic stenosis. Its PASCAL PRECISION and Cardioband transcatheter valve repair systems are commercially available in Europe for mitral and tricuspid valve repair.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Edwards Lifesciences Corp revenues increased 8% to $2.73B. Net income before extraordinary items increased 25% to $695.3M. Revenues reflect Transcatheter Aortic Valve Replacement segment increase of 6% to $2.05B, Transcatheter Mitral and Tricuspid Therapies segment increase of 75% to $155.9M, Critical Care segment increase of 13% to $251.3M, United States segment increase of 9% to $1.76B.